www.icahn.mssm.edu/cme/courses

LIVER CANCER:FROM BENCH TO CLINIC

Friday, December 18, 2015

Mount Sinai Liver Cancer Program

10th Anniversary

Icahn Medical Institute Icahn School of Medicine at Mount Sinai Goldwurm Auditorium 1425 Madison Avenue at 98th Street New York, NY

Program Director

JOSEP M. LLOVET, MDProfessor of MedicineDirector, Mount Sinai Liver Cancer Program

Sponsored byMount Sinai Liver Cancer ProgramThe Icahn School of Medicine at Mount Sinai

Co

mp

lim

en

tary

Re

gis

tra

tio

n O

nlin

e:

ww

w.ica

hn

.mss

m.e

du

/cm

e/c

ou

rse

s

Location Icahn Medical Institute Goldwurm Auditorium 1425 Madison Avenue at 98th Street New York, NY

Icahn School of Medicine at Mount Sinai FacultyProgram DirectorJOSEP M. LLOVET, MD, Professor of MedicineDirector, Mount Sinai Liver Cancer Program

Program Chairs SCOTT L. FRIEDMAN, MD, Professor of Medicine, Dean for Therapeutic Discovery

MYRON SCHWARTZ, MD, Professor of Surgery, Director of Liver Surgery

SAMUEL WAXMAN, MD, Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences

Activity Description This conference will assemble multidisciplinary experts on liver cancer from the Mount Sinai Liver Cancer Program and 2 outstanding invited lecturers. The meeting is intended to provide a summary of the state-of-the-art knowledge of the pathogenesis and clinical management of liver cancer, and the research conducted in Mount Sinai.

Activity Learning Objectives • Assess and classify the basic molecular alterations in HCC and cholangiocarcinoma • Review the impact of novel anti-viral therapies in development of HCC• Describe the current management of HCC and novel prospects• Evaluate novel therapies to be approved in liver cancer

Registration FeeComplimentary Register Online www.icahn.mssm.edu/cme/courses

Target Audience Hepatologists and Gastroenterologist, Oncologists, Surgeons, Radiologist, Pathologists and Basic Scientists interested in liver cancer from the New York Area.

AccreditationThe Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit DesignationThe Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Verification of AttendanceVerification of attendance will be provided to all professionals.

Special NeedsThe Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

AcknowledgmentSupported by education grants from:

Bayer HealthCare, Blueprint Medicines, BTG International, Gilead Sciences

LIVER CANCER: FROM BENCH TO CLINICFriday, December 18, 2015

PROGRAM

8:30 – 9:00am Registration

9:00 – 9:10am Welcome and Opening Steven Burakoff, MD Director, Tisch Cancer Institute

9:10 – 9:40am Achievements of Mount Sinai Liver Cancer Program 2005-15 Josep M. Llovet, MD Mount Sinai Liver Cancer Program, Division of Liver Diseases

9:40 – 10:15am Hans Popper Lecture: Introduction: Scott L. Friedman, MD Mount Sinai Liver Cancer Program, Division of Liver Diseases

New Experimental Models for Liver Cancer Scott W. Lowe, PhD Memorial Sloan Kettering Cancer Center, New York, NY

10:15 – 10:30am Coffee Break

PREVENTION AND SURGICAL THERAPIES OF HCCChairman: Myron Schwartz, MD, Mount Sinai Liver Cancer Program,

Department of Surgery

10:30 – 10:50am Overview of HCV Treatments and Outcomes Ira Jacobson, MD Site Chair, Department of Medicine Mount Sinai Beth Israel

10:50 – 11:10am Impact of Novel Antiviral Therapies in the Development of HCC Ponni Perumalswami, MD Division of Liver Diseases

11:10 – 11:30am Pathological Markers that Define Primary Liver Cancers M. Isabel Fiel, MD Mount Sinai Liver Cancer Program, Department of Pathology

11:30 – 11:50am Surgical Management of HCC: New Trends Myron Schwartz, MD Mount Sinai Liver Cancer Program, Department of Surgery

11:50 – 12:30pm Lunch

2nd Annual NYC Pain SymposiumLIVER CANCER:

FROM BENCH TO CLINIC

Mount Sinai Liver Cancer Program10th Anniversary

FRIDAY, DECEMBER 18, 2015

MANAGEMENT OF INTERMEDIATE/ ADVANCED LIVER CANCER: Chairman: Josep M. Llovet, MD, Mount Sinai Liver Cancer Program,

Division of Liver Diseases

12:30 – 12:50pm Management and Indications of TACE and TARE Edward Kim, MD Mount Sinai Liver Cancer Program, Department of Radiology

12:50 – 1:10pm Overview of Novel Agents in Phase II and Phase III-Opportunities in HCC

Josep M. Llovet, MD Mount Sinai Liver Cancer Program, Division of Liver Diseases

1:10 – 1:30pm Assessing Response with mRECIST after TACE and Systemic Therapies

Bachir Taouli, MD Mount Sinai Liver Cancer Program, Department of Radiology

1:30 – 1:50pm Overview of Management of Advanced ICC Celina Ang, MD Mount Sinai Liver Cancer Program, Division of Hematology and Medical Oncology

2:00 – 2:20pm Coffee Break

2:20 – 3:00pm State-of-the-art Lecture: Introduction: Samuel Waxman, MD Department of Hematology and Medical Oncology Department of Oncological Sciences

Exploring Origins of Cholangiocarcinoma with GEMM Supriya K. Saha, MD, PhD Massachusetts General Hospital, Boston, MA

NOVEL DRIVERS OF HEPATOCARCINOGENESISChairman: Scott L. Friedman, MD, Mount Sinai Liver Cancer Program,

Division of Liver Diseases

3:00 – 3:20pm Discovery of Novel Targets for Treating Intrahepatic CC Daniela Sia, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases

3:20 – 3:40pm Overview of Drivers, and How to Discover Novel Targets in HCC Amaia Lujambio, PhD Mount Sinai Liver Cancer Program, Department of Oncological Sciences

3:40 – 4:00pm Liquid Biopsy in Liver Cancer: Clinical Implications Augusto Villanueva, MD, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases

4:00 – 4:20pm Molecular Signatures in HCC: Clinical Translation Yujin Hoshida, MD, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases

4:20 – 4:40pm Linking Fibrosis, Autophagy and HCC Youngmin Lee, MD, PhD Mount Sinai Liver Cancer Program, Division of Liver Diseases

4:40 pm Closing Remarks

Mount Sinai Liver Cancer Program

10th Anniversary

LAST NAME FIRST NAME Degree

ADDRESS

CITY STATE ZIP

TELEPHONE E-MAIL

INSTITUTION/AFFILIATION

Confirmation will be sent via e-mail

Registration Fee: Complimentary

Register Online at: www.icahn.mssm.edu/cme/courses

Conference Information www.icahn.mssm.edu/cme/courses

Office of CME at 212-731-7950 e-mail: cme@mssm.edu

Cancellation Policy: All cancellations must be e-mailed to cme@mssm.edu no later than December 7, 2015.

LIVER CANCER:FROM BENCH TO CLINICFriday, December 18, 2015

Ica

hn

Sch

oo

l o

f M

ed

icin

e a

t M

ou

nt

Sin

ai

Th

e P

ag

e a

nd

Will

iam

Bla

ck P

ost

Gra

du

ate

Sch

oo

lO

ne

Gu

sta

ve L

. Le

vy P

lace

, Bo

x 11

93

Ne

w Y

ork

, NY

10

02

9-6

574

Icah

n M

edic

al In

stit

ute

Ic

ahn

Sch

oo

l of M

edic

ine

at M

ou

nt

Sin

ai

Go

ldw

urm

Au

dito

riu

m

LIV

ER C

AN

CER

:FR

OM

BEN

CH

TO

CLI

NIC

Fri

da

y, D

ece

mb

er

18, 2

015

MO

UN

T S

INA

I LI

VE

R C

AN

CE

R P

RO

GR

AM

10th

An

niv

ersa

ry

Co

mp

lim

en

tary

Re

gis

tra

tio

n O

nlin

e:

ww

w.ica

hn

.mss

m.e

du

/cm

e/c

ou

rse

s